缬沙坦对原发性高血压患者血管内皮功能的影响

为研究缬沙坦的降压疗效及其对血管内皮功能的影响 ,选择 89例初诊原发性高血压患者 ,口服缬沙坦 (80mg/d) 4周 ,观察治疗前后诊室血压及血浆内皮素 (ET)和一氧化氮 (NO)浓度的变化 ;另选 3 6例非药物治疗的原发性高血压患者为对照组。发现 :治疗组于缬沙坦治疗 4周后诊室收缩压和舒张压的下降幅度分别为 (2 .2 2± 0 .3 6)kPa〔(1 6.68± 2 .69)mmHg〕和 (1 .5 5± 0 .45 )kPa〔(1 1 .67± 3 .3 9)mmHg〕(P <0 .0 0 1 ) ;血浆内皮素质量浓度降低 (P <0 .0 5 ) ,NO浓度升高 (P <0 .0 0 1 ) ;NO/ET比值明显升高 (P <0 .0 0 1 ) ;对照组上述参数均无明显变化。提示 :缬沙坦在有效降压的同时能够改善血管内皮功能

Effects of Valsartan on Vascular Endothelial Function in Patients with Essential Hypertension

To investigate the effects of Valsartan on endothelial function and its antihypertensive efficacy, the changes of plasma endothelin(ET), nitrogen monoxide(NO) and clinical blood pressure(CBP) were observed before and after Valsartan was taken for four weeks in₈₉ patients with essential hypertension and 36 patients without drug therapy. After the four-week treatment of Valsartan, decreasing values of clinical systolic blood pressure and clinical diastolic blood pressure were (2.22±0.36) kPa〔(16.68±2.69) mmHg〕 and (1.55±0.45) kPa〔(11.67± 3.39) mmHg〕 respectively(P<0.001); ETdecreased and NOincreased (P<0.05 and 0.001 respectively), odds of NO/ET increased significantly(P< 0.001). These data did not have any changes in control group. It is suggested that Valsartan can decrease blood pressure effectively and improve vascular endothelial function simultaneously.